KR20150041651A - 피라졸 카복스아미드 화합물, 조성물 및 사용 방법 - Google Patents
피라졸 카복스아미드 화합물, 조성물 및 사용 방법 Download PDFInfo
- Publication number
- KR20150041651A KR20150041651A KR1020157006025A KR20157006025A KR20150041651A KR 20150041651 A KR20150041651 A KR 20150041651A KR 1020157006025 A KR1020157006025 A KR 1020157006025A KR 20157006025 A KR20157006025 A KR 20157006025A KR 20150041651 A KR20150041651 A KR 20150041651A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- independently
- alkylene
- cycloalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C*(Cc1c(C)[n](*)nc1*(O)=O)CI Chemical compound C*(Cc1c(C)[n](*)nc1*(O)=O)CI 0.000 description 32
- DSBXCIXDUULTMD-UHFFFAOYSA-N Nc1c[n](Cc2cc(C#N)ccc2)nc1 Chemical compound Nc1c[n](Cc2cc(C#N)ccc2)nc1 DSBXCIXDUULTMD-UHFFFAOYSA-N 0.000 description 3
- HKIIDGKOOZXNQC-UHFFFAOYSA-N Nc1c[n](Cc2ccccc2)nc1 Chemical compound Nc1c[n](Cc2ccccc2)nc1 HKIIDGKOOZXNQC-UHFFFAOYSA-N 0.000 description 3
- KBNVXLZPZMVNEN-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C3CCN(C)CC3)c3ccccc3)nc1)=O)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C3CCN(C)CC3)c3ccccc3)nc1)=O)n[nH]2 KBNVXLZPZMVNEN-UHFFFAOYSA-N 0.000 description 2
- DEWWGRMBFONECQ-UHFFFAOYSA-N CN(C)CCC(c1ccccc1)[n]1ncc(N)c1 Chemical compound CN(C)CCC(c1ccccc1)[n]1ncc(N)c1 DEWWGRMBFONECQ-UHFFFAOYSA-N 0.000 description 2
- JSRLURSZEMLAFO-UHFFFAOYSA-N Brc1cc(Br)ccc1 Chemical compound Brc1cc(Br)ccc1 JSRLURSZEMLAFO-UHFFFAOYSA-N 0.000 description 1
- VKZADARPOUVUIA-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCC(c1ccccc1)O)=O Chemical compound CC(C)(C)OC(N(C)CCC(c1ccccc1)O)=O VKZADARPOUVUIA-UHFFFAOYSA-N 0.000 description 1
- APHLRLDBYJWASR-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCC(c1ccccc1)[n]1ncc(N)c1)=O Chemical compound CC(C)(C)OC(N(C)CCC(c1ccccc1)[n]1ncc(N)c1)=O APHLRLDBYJWASR-UHFFFAOYSA-N 0.000 description 1
- YMOKMTYNABVEOL-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1C(c1cc(C)ccc1)O)=O Chemical compound CC(C)(C)OC(N(C1)CC1C(c1cc(C)ccc1)O)=O YMOKMTYNABVEOL-UHFFFAOYSA-N 0.000 description 1
- HZXHBDLOVLQJMY-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1C(c1cc(C)ccc1)[n]1ncc(N)c1)=O Chemical compound CC(C)(C)OC(N(C1)CC1C(c1cc(C)ccc1)[n]1ncc(N)c1)=O HZXHBDLOVLQJMY-UHFFFAOYSA-N 0.000 description 1
- MYQLRGRAAOKTAS-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C(c1ccccc1)[n]1ncc(N)c1)F)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C(c1ccccc1)[n]1ncc(N)c1)F)=O MYQLRGRAAOKTAS-UHFFFAOYSA-N 0.000 description 1
- ITLCXSHKUNNAHG-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(c1ccccc1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(c1ccccc1)=O)=O ITLCXSHKUNNAHG-UHFFFAOYSA-N 0.000 description 1
- BWMNOXJVRHGUQM-UHFFFAOYSA-N CC(C)(C1)OCCC1=O Chemical compound CC(C)(C1)OCCC1=O BWMNOXJVRHGUQM-UHFFFAOYSA-N 0.000 description 1
- VFFKDTIEEFHDFN-UHFFFAOYSA-N CC(C)(C1)OCCc2c1[nH]nc2C(Nc1c[n](Cc2ccccc2)nc1)=O Chemical compound CC(C)(C1)OCCc2c1[nH]nc2C(Nc1c[n](Cc2ccccc2)nc1)=O VFFKDTIEEFHDFN-UHFFFAOYSA-N 0.000 description 1
- XEYYHIIUOPQQSR-UHFFFAOYSA-N CC(C)(C1)OCCc2c1c(C(Nc1c[n](Cc3ccccc3)nc1)=O)n[nH]2 Chemical compound CC(C)(C1)OCCc2c1c(C(Nc1c[n](Cc3ccccc3)nc1)=O)n[nH]2 XEYYHIIUOPQQSR-UHFFFAOYSA-N 0.000 description 1
- CIXNCIDCNSKBGZ-UHFFFAOYSA-O CC(C)(CC1)Cc2c1c(C(NC(C=N)=C[NH2+]C(CCN(C)C)c1ccccc1)=O)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(C(NC(C=N)=C[NH2+]C(CCN(C)C)c1ccccc1)=O)n[nH]2 CIXNCIDCNSKBGZ-UHFFFAOYSA-O 0.000 description 1
- NXNRZEJOKBBSTL-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C(C3)CS3(=O)=O)c3ccccc3)nc1)=O)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C(C3)CS3(=O)=O)c3ccccc3)nc1)=O)n[nH]2 NXNRZEJOKBBSTL-UHFFFAOYSA-N 0.000 description 1
- WYYQOCMJSGRWMJ-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C(CC3)CCS3(=O)=O)c3ncc[s]3)nc1)=O)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C(CC3)CCS3(=O)=O)c3ncc[s]3)nc1)=O)n[nH]2 WYYQOCMJSGRWMJ-UHFFFAOYSA-N 0.000 description 1
- FKEPDKSUARYYJA-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C(CC3)CC[N+]3(C)[O-])c3ccccc3)nc1)=O)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C(CC3)CC[N+]3(C)[O-])c3ccccc3)nc1)=O)n[nH]2 FKEPDKSUARYYJA-UHFFFAOYSA-N 0.000 description 1
- SDIIYFQWCHUACH-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C3CN(CCF)C3)c3ccccc3)nc1)=O)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(C3CN(CCF)C3)c3ccccc3)nc1)=O)n[nH]2 SDIIYFQWCHUACH-UHFFFAOYSA-N 0.000 description 1
- LSVHNOXPQYWHQO-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(CCC#N)c3cnccc3)nc1)=O)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(CCC#N)c3cnccc3)nc1)=O)n[nH]2 LSVHNOXPQYWHQO-UHFFFAOYSA-N 0.000 description 1
- VCGQMNXNXZUWMA-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(CN(CCOC3)C3=O)c3ccccc3)nc1)=O)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(CN(CCOC3)C3=O)c3ccccc3)nc1)=O)n[nH]2 VCGQMNXNXZUWMA-UHFFFAOYSA-N 0.000 description 1
- VRORKYZHKNPCSI-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(CS(C)(=O)=O)c3cnccc3)nc1)=O)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(C(Nc1c[n](C(CS(C)(=O)=O)c3cnccc3)nc1)=O)n[nH]2 VRORKYZHKNPCSI-UHFFFAOYSA-N 0.000 description 1
- SDZFNFGEAWBFTM-UHFFFAOYSA-N CC(C1)(C2)C1Cc1c2[nH]nc1C(Nc1c[n](C(C(CC2)CCS2(=O)=O)c2ccccc2)nc1)=O Chemical compound CC(C1)(C2)C1Cc1c2[nH]nc1C(Nc1c[n](C(C(CC2)CCS2(=O)=O)c2ccccc2)nc1)=O SDZFNFGEAWBFTM-UHFFFAOYSA-N 0.000 description 1
- MSNWXGOLLSBLME-UHFFFAOYSA-N CC(C1)(C2)C1Cc1c2[nH]nc1C(Nc1c[n](C(C(CCCC2)S2(=O)=O)c2ccccc2)nc1)=O Chemical compound CC(C1)(C2)C1Cc1c2[nH]nc1C(Nc1c[n](C(C(CCCC2)S2(=O)=O)c2ccccc2)nc1)=O MSNWXGOLLSBLME-UHFFFAOYSA-N 0.000 description 1
- GPCBTAQXTZJOFF-UHFFFAOYSA-N CC(CC1)(CCC1=O)N1CCOCC1 Chemical compound CC(CC1)(CCC1=O)N1CCOCC1 GPCBTAQXTZJOFF-UHFFFAOYSA-N 0.000 description 1
- MOMFXATYAINJML-UHFFFAOYSA-N CC(c1ncc[s]1)=O Chemical compound CC(c1ncc[s]1)=O MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
- XUFGSMOFWKAELZ-UHFFFAOYSA-N CC(c1ncc[s]1)[n]1ncc(N)c1 Chemical compound CC(c1ncc[s]1)[n]1ncc(N)c1 XUFGSMOFWKAELZ-UHFFFAOYSA-N 0.000 description 1
- JCHWHOHZZYWUMP-UHFFFAOYSA-N CC1(C)OB(C(CC2)=CCC22OCCO2)OC1(C)C Chemical compound CC1(C)OB(C(CC2)=CCC22OCCO2)OC1(C)C JCHWHOHZZYWUMP-UHFFFAOYSA-N 0.000 description 1
- XXRLJXZVZZXDPP-UHFFFAOYSA-N CCOC(C(c1ccccc1)Cl)=O Chemical compound CCOC(C(c1ccccc1)Cl)=O XXRLJXZVZZXDPP-UHFFFAOYSA-N 0.000 description 1
- OZNPGHPUFOIURR-UHFFFAOYSA-N CCOC(C(c1ccccc1)[n]1ncc(N)c1)=O Chemical compound CCOC(C(c1ccccc1)[n]1ncc(N)c1)=O OZNPGHPUFOIURR-UHFFFAOYSA-N 0.000 description 1
- ZUBSBBLBZPIWML-UHFFFAOYSA-N CC[n]1ncc(C(C)[n]2ncc(N)c2)c1 Chemical compound CC[n]1ncc(C(C)[n]2ncc(N)c2)c1 ZUBSBBLBZPIWML-UHFFFAOYSA-N 0.000 description 1
- TVZMTJMOHLFIQK-UHFFFAOYSA-N CC[n]1ncc(C(C)[n]2ncc(NC(c3n[nH]c4c3CCC(C)(C)C4)=O)c2)c1 Chemical compound CC[n]1ncc(C(C)[n]2ncc(NC(c3n[nH]c4c3CCC(C)(C)C4)=O)c2)c1 TVZMTJMOHLFIQK-UHFFFAOYSA-N 0.000 description 1
- VUXWPPSAMPSGCH-UHFFFAOYSA-N CN(C)CCC(c1ccccc1)[n]1ncc(NC(c2n[nH]c3c2C(C2)C2CC3)=O)c1 Chemical compound CN(C)CCC(c1ccccc1)[n]1ncc(NC(c2n[nH]c3c2C(C2)C2CC3)=O)c1 VUXWPPSAMPSGCH-UHFFFAOYSA-N 0.000 description 1
- BKWOLKHZXFBGOG-UHFFFAOYSA-N CN(CC1)CCC1C(c1ccccc1)[n]1ncc(N)c1 Chemical compound CN(CC1)CCC1C(c1ccccc1)[n]1ncc(N)c1 BKWOLKHZXFBGOG-UHFFFAOYSA-N 0.000 description 1
- BDWRHMZCOHLHRB-UHFFFAOYSA-N CNc1cccc(C[n]2ncc(NC(c3n[nH]c(C4)c3CCC4O)=O)c2)c1 Chemical compound CNc1cccc(C[n]2ncc(NC(c3n[nH]c(C4)c3CCC4O)=O)c2)c1 BDWRHMZCOHLHRB-UHFFFAOYSA-N 0.000 description 1
- QCRGSLJHRIUBNK-UHFFFAOYSA-N COC(CCC(CC1)(CCC1=O)[N+]([O-])=O)=O Chemical compound COC(CCC(CC1)(CCC1=O)[N+]([O-])=O)=O QCRGSLJHRIUBNK-UHFFFAOYSA-N 0.000 description 1
- OWKMEXGEZRXATB-UHFFFAOYSA-N CSCC(c1cccnc1)[n]1ncc(N)c1 Chemical compound CSCC(c1cccnc1)[n]1ncc(N)c1 OWKMEXGEZRXATB-UHFFFAOYSA-N 0.000 description 1
- FRTNXLCPHOKIOK-UHFFFAOYSA-N CSc1cccc(C(C2CC2)[n]2ncc(N)c2)c1 Chemical compound CSc1cccc(C(C2CC2)[n]2ncc(N)c2)c1 FRTNXLCPHOKIOK-UHFFFAOYSA-N 0.000 description 1
- MBLYXJIPOWYSTF-UHFFFAOYSA-N CSc1cccc(C(C2COCC2)[n]2ncc(N)c2)c1 Chemical compound CSc1cccc(C(C2COCC2)[n]2ncc(N)c2)c1 MBLYXJIPOWYSTF-UHFFFAOYSA-N 0.000 description 1
- UZNVPQBEYFYUJG-UHFFFAOYSA-N C[N](C)(CCC1(CC2)CCC2=O)C1=O Chemical compound C[N](C)(CCC1(CC2)CCC2=O)C1=O UZNVPQBEYFYUJG-UHFFFAOYSA-N 0.000 description 1
- VXTVEKSYDOVTSB-UHFFFAOYSA-N C[O](CC1)CC1(CC1)CCC1=O Chemical compound C[O](CC1)CC1(CC1)CCC1=O VXTVEKSYDOVTSB-UHFFFAOYSA-N 0.000 description 1
- CTMIRSXLUGHAPS-UHFFFAOYSA-N C[n]1ncc(C(c2ccccc2)[n]2ncc(N)c2)c1 Chemical compound C[n]1ncc(C(c2ccccc2)[n]2ncc(N)c2)c1 CTMIRSXLUGHAPS-UHFFFAOYSA-N 0.000 description 1
- ROSFKGHTACMLTG-UHFFFAOYSA-N C[n]1ncc(C(c2ccccc2)[n]2ncc(NC(c3n[nH]c4c3C(C3)C3CC4)=O)c2)c1 Chemical compound C[n]1ncc(C(c2ccccc2)[n]2ncc(NC(c3n[nH]c4c3C(C3)C3CC4)=O)c2)c1 ROSFKGHTACMLTG-UHFFFAOYSA-N 0.000 description 1
- NRJLSFKZAQFLCT-UHFFFAOYSA-N N#Cc1cc(C[n]2ncc(NC(c3n[nH]c(CC4)c3CC4c3c[nH]nc3)=O)c2)ccc1 Chemical compound N#Cc1cc(C[n]2ncc(NC(c3n[nH]c(CC4)c3CC4c3c[nH]nc3)=O)c2)ccc1 NRJLSFKZAQFLCT-UHFFFAOYSA-N 0.000 description 1
- KQOCZYJNQQTYIM-UHFFFAOYSA-N N#Cc1cccc(C(C2CCSCC2)O)c1 Chemical compound N#Cc1cccc(C(C2CCSCC2)O)c1 KQOCZYJNQQTYIM-UHFFFAOYSA-N 0.000 description 1
- GPDQRGLXYDGJIF-UHFFFAOYSA-N N#Cc1cccc(C[n]2ncc(NC(c3n[nH]c(C4)c3CCC4c3c[nH]nc3)=O)c2)c1 Chemical compound N#Cc1cccc(C[n]2ncc(NC(c3n[nH]c(C4)c3CCC4c3c[nH]nc3)=O)c2)c1 GPDQRGLXYDGJIF-UHFFFAOYSA-N 0.000 description 1
- AOGHGJYOHJQMBZ-UHFFFAOYSA-N Nc1c[n](C(C(C2)CS2(=O)=O)c2ccccc2)nc1 Chemical compound Nc1c[n](C(C(C2)CS2(=O)=O)c2ccccc2)nc1 AOGHGJYOHJQMBZ-UHFFFAOYSA-N 0.000 description 1
- HQHZMEFSCHLNQC-UHFFFAOYSA-N Nc1c[n](C(C(CC2)CCS2(=O)=O)c2cc(C#N)ccc2)nc1 Chemical compound Nc1c[n](C(C(CC2)CCS2(=O)=O)c2cc(C#N)ccc2)nc1 HQHZMEFSCHLNQC-UHFFFAOYSA-N 0.000 description 1
- XTAUGLXXDLELNU-UHFFFAOYSA-N Nc1c[n](C(C(CC2)CCS2(=O)=O)c2ccccc2)nc1 Chemical compound Nc1c[n](C(C(CC2)CCS2(=O)=O)c2ccccc2)nc1 XTAUGLXXDLELNU-UHFFFAOYSA-N 0.000 description 1
- HCKRWAQXQSMJDR-UHFFFAOYSA-N Nc1c[n](C(C(CC2)CCS2=O)c2cnccc2)nc1 Chemical compound Nc1c[n](C(C(CC2)CCS2=O)c2cnccc2)nc1 HCKRWAQXQSMJDR-UHFFFAOYSA-N 0.000 description 1
- PFAUHPQTLJNSND-UHFFFAOYSA-N Nc1c[n](C(C(CCCC2)S2(=O)=O)c2ccccc2)nc1 Chemical compound Nc1c[n](C(C(CCCC2)S2(=O)=O)c2ccccc2)nc1 PFAUHPQTLJNSND-UHFFFAOYSA-N 0.000 description 1
- DPQTYXJLWNUYIC-UHFFFAOYSA-N Nc1c[n](C(C2CCN(CCF)CC2)c2ccccc2)nc1 Chemical compound Nc1c[n](C(C2CCN(CCF)CC2)c2ccccc2)nc1 DPQTYXJLWNUYIC-UHFFFAOYSA-N 0.000 description 1
- SDGUZZKLWJEZNQ-UHFFFAOYSA-N Nc1c[n](C(C2CCSCC2)c2ncc[s]2)nc1 Chemical compound Nc1c[n](C(C2CCSCC2)c2ncc[s]2)nc1 SDGUZZKLWJEZNQ-UHFFFAOYSA-N 0.000 description 1
- HDEHILFYBCXGJF-UHFFFAOYSA-N Nc1c[n](C(C2CN(CCF)C2)c2ccccc2)nc1 Chemical compound Nc1c[n](C(C2CN(CCF)C2)c2ccccc2)nc1 HDEHILFYBCXGJF-UHFFFAOYSA-N 0.000 description 1
- ZVDYQRUQMUNOAF-UHFFFAOYSA-N Nc1c[n](C(CCC#N)c2cnccc2)nc1 Chemical compound Nc1c[n](C(CCC#N)c2cnccc2)nc1 ZVDYQRUQMUNOAF-UHFFFAOYSA-N 0.000 description 1
- SOPROCCKHSSHJC-UHFFFAOYSA-N Nc1c[n](C(CN(CCOC2)C2=O)c2ccccc2)nc1 Chemical compound Nc1c[n](C(CN(CCOC2)C2=O)c2ccccc2)nc1 SOPROCCKHSSHJC-UHFFFAOYSA-N 0.000 description 1
- VKRKCBWIVLSRBJ-UHFFFAOYSA-N O=C(CC1)CCC11OCCO1 Chemical compound O=C(CC1)CCC11OCCO1 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 1
- BDNIPQNRQTZZFQ-UHFFFAOYSA-N O=C(CC1)CCC1c1cncnc1 Chemical compound O=C(CC1)CCC1c1cncnc1 BDNIPQNRQTZZFQ-UHFFFAOYSA-N 0.000 description 1
- XJEZEQWBGAOABI-UHFFFAOYSA-N O=C(c1n[nH]c2c1CC1CC2C1)Nc1c[n](Cc2ccccc2)nc1 Chemical compound O=C(c1n[nH]c2c1CC1CC2C1)Nc1c[n](Cc2ccccc2)nc1 XJEZEQWBGAOABI-UHFFFAOYSA-N 0.000 description 1
- GSUBXIVOZXWGKF-UHFFFAOYSA-N O=CC1COCC1 Chemical compound O=CC1COCC1 GSUBXIVOZXWGKF-UHFFFAOYSA-N 0.000 description 1
- AQEFFKPOBZPJQM-UHFFFAOYSA-N OC(C1CCN(CCF)CC1)c1ccccc1 Chemical compound OC(C1CCN(CCF)CC1)c1ccccc1 AQEFFKPOBZPJQM-UHFFFAOYSA-N 0.000 description 1
- UYSMVWVQDHNCCW-UHFFFAOYSA-N [O-][N+](c1c[n](C(C2CCSCC2)c2cnccc2)nc1)=O Chemical compound [O-][N+](c1c[n](C(C2CCSCC2)c2cnccc2)nc1)=O UYSMVWVQDHNCCW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682063P | 2012-08-10 | 2012-08-10 | |
| US61/682,063 | 2012-08-10 | ||
| US201361764434P | 2013-02-13 | 2013-02-13 | |
| US61/764,434 | 2013-02-13 | ||
| US201361764930P | 2013-02-14 | 2013-02-14 | |
| US61/764,930 | 2013-02-14 | ||
| PCT/CN2013/081136 WO2014023258A1 (en) | 2012-08-10 | 2013-08-09 | Pyrazole carboxamide compounds, compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150041651A true KR20150041651A (ko) | 2015-04-16 |
Family
ID=50067432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157006025A Abandoned KR20150041651A (ko) | 2012-08-10 | 2013-08-09 | 피라졸 카복스아미드 화합물, 조성물 및 사용 방법 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150158851A1 (https=) |
| EP (1) | EP2882718A4 (https=) |
| JP (1) | JP2015528435A (https=) |
| KR (1) | KR20150041651A (https=) |
| CN (1) | CN104781238A (https=) |
| AR (1) | AR092088A1 (https=) |
| BR (1) | BR112015002938A2 (https=) |
| CA (1) | CA2880232A1 (https=) |
| HK (1) | HK1212344A1 (https=) |
| MX (1) | MX2015001864A (https=) |
| RU (1) | RU2015106013A (https=) |
| TW (1) | TW201410654A (https=) |
| WO (1) | WO2014023258A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201706102D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| WO2019195810A2 (en) * | 2018-04-06 | 2019-10-10 | Praxis Biotech LLC | Atf6 inhibitors and uses thereof |
| EP4077316A1 (en) | 2019-12-20 | 2022-10-26 | Pfizer Inc. | Benzimidazole derivatives |
| US20250002489A1 (en) * | 2021-10-19 | 2025-01-02 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004508359A (ja) * | 2000-09-06 | 2004-03-18 | ニューロゲン コーポレイション | アリール置換テトラヒドロインダゾール、及び、gaba−a受容体に対するリガンドとしてのそれらの使用 |
| CA2465326C (en) * | 2001-11-01 | 2011-03-29 | Icagen, Inc. | Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel |
| EP1472252A1 (en) * | 2002-02-07 | 2004-11-03 | Neurogen Corporation | Substituted fused pyrazolecarboxylic acid arylamides and related compounds |
| FR2845382A1 (fr) * | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique |
| CA2669736C (en) * | 2005-11-03 | 2017-02-21 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| WO2011071725A1 (en) * | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| AU2011329233A1 (en) * | 2010-11-15 | 2013-05-23 | Abbvie Deutschland Gmbh & Co Kg | NAMPT and ROCK inhibitors |
| KR20140047160A (ko) * | 2011-08-12 | 2014-04-21 | 에프. 호프만-라 로슈 아게 | 인다졸 화합물, 조성물 및 사용 방법 |
-
2013
- 2013-08-09 RU RU2015106013A patent/RU2015106013A/ru unknown
- 2013-08-09 HK HK16100276.7A patent/HK1212344A1/xx unknown
- 2013-08-09 WO PCT/CN2013/081136 patent/WO2014023258A1/en not_active Ceased
- 2013-08-09 MX MX2015001864A patent/MX2015001864A/es unknown
- 2013-08-09 BR BR112015002938A patent/BR112015002938A2/pt not_active Application Discontinuation
- 2013-08-09 AR ARP130102838A patent/AR092088A1/es unknown
- 2013-08-09 KR KR1020157006025A patent/KR20150041651A/ko not_active Abandoned
- 2013-08-09 CN CN201380049541.7A patent/CN104781238A/zh active Pending
- 2013-08-09 TW TW102128696A patent/TW201410654A/zh unknown
- 2013-08-09 JP JP2015525727A patent/JP2015528435A/ja active Pending
- 2013-08-09 EP EP13827574.8A patent/EP2882718A4/en not_active Withdrawn
- 2013-08-09 CA CA2880232A patent/CA2880232A1/en not_active Abandoned
-
2015
- 2015-02-10 US US14/618,827 patent/US20150158851A1/en not_active Abandoned
-
2016
- 2016-05-11 US US15/152,212 patent/US20160326142A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2882718A1 (en) | 2015-06-17 |
| CN104781238A (zh) | 2015-07-15 |
| TW201410654A (zh) | 2014-03-16 |
| WO2014023258A1 (en) | 2014-02-13 |
| CA2880232A1 (en) | 2014-02-13 |
| MX2015001864A (es) | 2015-05-15 |
| HK1212344A1 (en) | 2016-06-10 |
| RU2015106013A (ru) | 2016-10-10 |
| AR092088A1 (es) | 2015-03-25 |
| US20150158851A1 (en) | 2015-06-11 |
| US20160326142A1 (en) | 2016-11-10 |
| EP2882718A4 (en) | 2015-12-23 |
| JP2015528435A (ja) | 2015-09-28 |
| BR112015002938A2 (pt) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109476663B (zh) | 用于治疗癌症的吡唑并吡啶衍生物 | |
| JP5855253B2 (ja) | インダゾール化合物、組成物及び使用方法 | |
| US8461328B2 (en) | Tricyclic heterocyclic compounds, compositions and methods of use thereof | |
| CN116209438A (zh) | 使用sos1抑制剂治疗具有shp2突变的恶性疾病 | |
| JP6802263B2 (ja) | Tyk2阻害剤およびその使用 | |
| JP6771464B2 (ja) | Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物 | |
| CN115052627A (zh) | Irak降解剂和其用途 | |
| TW202227460A (zh) | Ras抑制劑 | |
| US20230122219A1 (en) | Irak degraders and uses thereof | |
| TW202444726A (zh) | Ras抑制劑 | |
| BR112016008276B1 (pt) | derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica | |
| CN115916194A (zh) | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 | |
| JP2018524350A (ja) | TBK/IKKε阻害剤化合物及びその用途 | |
| US12064421B2 (en) | Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors | |
| WO2022115879A1 (en) | Pyrrolidine derivatives and methods of use | |
| KR20150041651A (ko) | 피라졸 카복스아미드 화합물, 조성물 및 사용 방법 | |
| CN118973581A (zh) | Irak降解剂及其用途 | |
| HK40005958A (en) | Pyrazolopyridine derivatives for the treatment of cancer | |
| EA053196B1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam | |
| HK1176930A (en) | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20150309 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20150309 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160414 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20161031 |
|
| NORF | Unpaid initial registration fee | ||
| PC1904 | Unpaid initial registration fee |